Cenix Begins Target Validation Work for AstraZeneca
Cenix BioScience announced this week that it has begun a second research project under an existing arrangement with AstraZeneca.
According to Cenix, the new project will focus on cell-based studies to advance the validation of novel oncology-target candidates recently identified by the company in RNAi screens conducted for AstraZeneca.
Specific terms of the new agreement were not disclosed.
RXi Q4 Losses Rise on Higher R&D Spending, Delivery Technology License